Another solstice for CTLA-4
Solstice Oncology acquires porustobart from Harbour Biomed.
Ideaya’s first pivotal catalyst looms
Darovasertib data are promised for the last week of March.
MAT2A inhibition gets another endorsement
Gilead opting against IDE397 is still good news for Ideaya.
Compass points the way towards its next readout
Progression-free and overall survival data from Companion-002 are due this quarter.
Astra’s Claudin reckoning approaches
Pivotal data are due soon with the Claudin18.2-targeting ADC sonesitatug vedotin.
VEGF bispecifics enter the conjugate era
JSKN027 will become the first ADC with this mechanism to enter human trials.
NK-cell engagers see another discontinuation
BeOne terminates a MUC1-targeting project.
